Shannon N. Westin, MD, MPH, discusses the promising results of the ENPAC trial that showed the effectiveness of adding enzalutamide to standard of care chemotherapy for patients with recurrent endometriod cancer.
Shannon N. Westin, MD, MPH
Advertisement
Articles by Shannon N. Westin, MD, MPH
Shannon N. Westin, MD, MPH, FACOG, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial.
Shannon N. Westin, MD, MPH, FACOG, discusses the evolving role of immunotherapy as treatment of patients with endometrial cancer.
Shannon N. Westin, MD, MPH, discusses resistance seen with PARP inhibitors in ovarian cancer and how this resistance can be overcome.
Advertisement
Latest Updated Articles
Overcoming Resistance to PARP Inhibitors in Ovarian CancerPublished: October 26th 2018 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
